MX2012003392A - Nuevo derivado de fenol. - Google Patents
Nuevo derivado de fenol.Info
- Publication number
- MX2012003392A MX2012003392A MX2012003392A MX2012003392A MX2012003392A MX 2012003392 A MX2012003392 A MX 2012003392A MX 2012003392 A MX2012003392 A MX 2012003392A MX 2012003392 A MX2012003392 A MX 2012003392A MX 2012003392 A MX2012003392 A MX 2012003392A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- lower alkyl
- salt
- derivative
- hydrogen atom
- Prior art date
Links
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical class OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000002829 nitrogen Chemical class 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 150000002989 phenols Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 230000003424 uricosuric effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen un nuevo compuesto y un producto farmacéutico, cada uno que tiene un efecto uricosúrica notable. Se describen de manera específica: un nuevo derivado de fenol representado por la fórmula general (1) que se muestra en la Fig. 1; una sal farmacéuticamente aceptable del mismo; un hidrato del derivado o la sal; y un solvato del derivado o la sal. (En la fórmula, R1 y R2 pueden ser los mismos o diferentes y cada uno representa un grupo alquilo inferior, un grupo alquenilo inferior, un grupo alquinilo inferior un grupo alcoxi inferior, un grupo haloalquilo, un grupo haloalcoxi, un grupo alquilsulfanilo, un grupo alquilsulfinilo, un grupo alquilsulfonilo, un grupo carbamoilo sustituido con alquilo inferior, un grupo N-carbonilo heterocícliclo que contiene nitrógeno saturado, un átomo de halógeno, un grupo ciano un átomo de hidrógeno; R3 representa un grupo alquilo inferior, un grupo haloalquilo, un átomo de halógeno, un grupo hidroxi un átomo de hidrógeno, y X representa un átomo de azufre, un grupo -S(=O)- o un grupo -S(=O)2-.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009227402A JP5325065B2 (ja) | 2009-09-30 | 2009-09-30 | 新規フェノール誘導体 |
| PCT/JP2010/066925 WO2011040449A1 (ja) | 2009-09-30 | 2010-09-29 | 新規フェノール誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012003392A true MX2012003392A (es) | 2012-04-10 |
Family
ID=43826265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012003392A MX2012003392A (es) | 2009-09-30 | 2010-09-29 | Nuevo derivado de fenol. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8367843B2 (es) |
| EP (1) | EP2484669B1 (es) |
| JP (1) | JP5325065B2 (es) |
| KR (1) | KR101647174B1 (es) |
| CN (1) | CN102639518B (es) |
| AU (1) | AU2010301675B2 (es) |
| BR (1) | BR112012007069B1 (es) |
| CA (1) | CA2775309C (es) |
| DK (1) | DK2484669T3 (es) |
| ES (1) | ES2549603T3 (es) |
| HU (1) | HUE026007T2 (es) |
| IL (1) | IL218519A (es) |
| IN (1) | IN2012DN02551A (es) |
| MX (1) | MX2012003392A (es) |
| MY (1) | MY160394A (es) |
| NZ (1) | NZ598582A (es) |
| PH (1) | PH12012500643A1 (es) |
| PL (1) | PL2484669T3 (es) |
| PT (1) | PT2484669E (es) |
| RU (1) | RU2536689C2 (es) |
| TW (1) | TWI461195B (es) |
| WO (1) | WO2011040449A1 (es) |
| ZA (1) | ZA201201895B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5851802B2 (ja) | 2011-03-30 | 2016-02-03 | 富士重工業株式会社 | 炭素繊維強化樹脂複合材用ドリル |
| WO2015191034A1 (en) * | 2014-06-09 | 2015-12-17 | Baylor College Of Medicine | Small molecule xanthine oxidase inhibitors and methods of use |
| WO2017038799A1 (ja) * | 2015-09-04 | 2017-03-09 | サントリーホールディングス株式会社 | ウレアーゼ活性阻害剤 |
| MX375068B (es) * | 2015-09-10 | 2025-03-06 | Jiangsu Atom Bioscience And Pharmaceutical Co Ltd | Un grupo de compuestos utilizados para el tratamiento o prevencion de hiperuricemia o gota. |
| CN105675557B (zh) * | 2016-01-07 | 2019-01-25 | 济南大学 | 基于苯炔荧光试剂检测硫脲含量的新方法 |
| PT3484862T (pt) | 2016-07-18 | 2021-11-17 | Arthrosi Therapeutics Inc | Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia |
| US10752601B2 (en) * | 2017-04-28 | 2020-08-25 | Fuji Yakuhin Co., Ltd | Crystal form and salt of 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole |
| CN109928890B (zh) * | 2017-12-15 | 2021-11-09 | 重庆常捷医药有限公司 | 一种托伐普坦中间体2-甲基-4-n-(2-甲基苯甲酰)苯甲酸的制备方法 |
| US12419854B2 (en) | 2018-12-06 | 2025-09-23 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing gout or hyperuricemia |
| AU2019394974B2 (en) | 2018-12-06 | 2025-08-28 | Arthrosi Therapeutics, Inc. | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| CA3159300A1 (en) * | 2019-12-09 | 2021-06-17 | Tadashi Inoue | Solid pharmaceutical preparation |
| CN111675675A (zh) * | 2020-07-17 | 2020-09-18 | 苏州明锐医药科技有限公司 | 多替诺德的制备方法 |
| CN111662247A (zh) * | 2020-07-17 | 2020-09-15 | 苏州明锐医药科技有限公司 | 一种多替诺德的合成方法 |
| CN112430221B (zh) * | 2020-11-20 | 2023-06-23 | 成都诺和晟泰生物科技有限公司 | 用于预防、治疗或减轻高尿酸血症或痛风的化合物及其应用 |
| WO2022169974A1 (en) | 2021-02-05 | 2022-08-11 | Nexys Therapeutics, Inc. | Inhibitors of urat1 and pharmaceutical uses thereof |
| CN114903879B (zh) * | 2022-06-23 | 2023-10-31 | 东北大学 | 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途 |
| CN115160314B (zh) * | 2022-07-28 | 2023-12-05 | 南方医科大学 | 杂环芳酰胺类化合物及其制备方法和应用 |
| WO2025085662A1 (en) | 2023-10-17 | 2025-04-24 | Vanderbilt University | Compounds for tocolytic use |
| CN118580197A (zh) * | 2023-11-16 | 2024-09-03 | 广东东阳光药业股份有限公司 | 一种多替诺雷制备方法及其应用 |
| CN119930540A (zh) * | 2025-01-21 | 2025-05-06 | 杭州善礼生物医药科技有限公司 | 一种多替诺雷的制备方法 |
| CN121226282A (zh) * | 2025-05-22 | 2025-12-30 | 武汉武药科技有限公司 | 一种化合物原料药及其药物组合物和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3720683A (en) * | 1970-09-02 | 1973-03-13 | Squibb & Sons Inc | 2-phenyl-3-acylbenzothiazolines and their oxides |
| WO2005121112A1 (ja) | 2004-06-10 | 2005-12-22 | Torii Pharmaceutical Co., Ltd. | ６－ヒドロキシベンズブロマロン又はその塩からなる医薬組成物 |
| AR051780A1 (es) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| JP3988832B2 (ja) | 2004-11-29 | 2007-10-10 | 日本たばこ産業株式会社 | 窒素含有縮合環化合物及びその用途 |
| WO2007086504A1 (ja) * | 2006-01-27 | 2007-08-02 | Japan Tobacco Inc. | カルボン酸化合物及びその用途 |
| US20080305169A1 (en) * | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
| US20080064871A1 (en) * | 2006-05-26 | 2008-03-13 | Japan Tobacco Inc. | Production Method of Nitrogen-Containing Fused Ring Compounds |
| WO2008062740A1 (fr) * | 2006-11-20 | 2008-05-29 | Japan Tobacco Inc. | Composé azoté à anneaux fusionnés et son utilisation |
-
2009
- 2009-09-30 JP JP2009227402A patent/JP5325065B2/ja active Active
-
2010
- 2010-09-29 WO PCT/JP2010/066925 patent/WO2011040449A1/ja not_active Ceased
- 2010-09-29 CN CN201080042866.9A patent/CN102639518B/zh active Active
- 2010-09-29 IN IN2551DEN2012 patent/IN2012DN02551A/en unknown
- 2010-09-29 HU HUE10820564A patent/HUE026007T2/en unknown
- 2010-09-29 US US13/499,190 patent/US8367843B2/en active Active
- 2010-09-29 PT PT108205642T patent/PT2484669E/pt unknown
- 2010-09-29 EP EP10820564.2A patent/EP2484669B1/en active Active
- 2010-09-29 RU RU2012117786/04A patent/RU2536689C2/ru active
- 2010-09-29 AU AU2010301675A patent/AU2010301675B2/en active Active
- 2010-09-29 MX MX2012003392A patent/MX2012003392A/es active IP Right Grant
- 2010-09-29 CA CA2775309A patent/CA2775309C/en active Active
- 2010-09-29 NZ NZ598582A patent/NZ598582A/xx unknown
- 2010-09-29 BR BR112012007069-0A patent/BR112012007069B1/pt active IP Right Grant
- 2010-09-29 PL PL10820564T patent/PL2484669T3/pl unknown
- 2010-09-29 PH PH1/2012/500643A patent/PH12012500643A1/en unknown
- 2010-09-29 MY MYPI2012001060A patent/MY160394A/en unknown
- 2010-09-29 TW TW099132910A patent/TWI461195B/zh active
- 2010-09-29 KR KR1020127007939A patent/KR101647174B1/ko active Active
- 2010-09-29 DK DK10820564.2T patent/DK2484669T3/en active
- 2010-09-29 ES ES10820564.2T patent/ES2549603T3/es active Active
-
2012
- 2012-03-07 IL IL218519A patent/IL218519A/en active IP Right Grant
- 2012-03-14 ZA ZA2012/01895A patent/ZA201201895B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012003392A (es) | Nuevo derivado de fenol. | |
| ES2662444T3 (es) | Derivado de piridina | |
| AR106237A2 (es) | Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables | |
| ES2601518T3 (es) | Composiciones plaguicidas | |
| PE20130239A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
| ECSP099335A (es) | Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos | |
| DK2069374T4 (da) | Krystallinske solvater af (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl)phenyl)-d-glucitolderivater med alkoholer som sglt2-inhibitorer til behandling af diabetes | |
| CL2008001017A1 (es) | Compuestos derivados de indol, activadores de glucoquinasa; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de diabetes u obesidad. | |
| AR065810A1 (es) | Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa. | |
| AR054425A1 (es) | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. | |
| ES2478823T3 (es) | Derivados de iminopiridina y uso de los mismos | |
| CY1112921T1 (el) | Ενεργοποιητες γλυκοκινασης πυρρολιδινονης | |
| AR078619A1 (es) | Derivados de ciclohexano espiro-condensados como inhibidores de hsl, utiles en el tratamiento de la diabetes | |
| MY148609A (en) | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer | |
| CR10027A (es) | Nuevos derivados de pirrol fusionado | |
| MX2007007845A (es) | Sulfonilpirrolidinas, metodo para producir las mismas y su uso como medicamento. | |
| AR110992A1 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas | |
| MX385586B (es) | Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia. | |
| CY1110034T1 (el) | Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν | |
| MX2010000658A (es) | Derivados de pirimidina 934. | |
| NO20075734L (no) | Tiofenforbindelser og trombopoietin reseptoractivatorer | |
| DOP2009000106A (es) | Compuestos de pirazol y triazol sustituídos como inhibidores de ksp | |
| EA201070839A1 (ru) | Новые производные ацилцианопирролидинов | |
| EA200970372A1 (ru) | Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение | |
| AR059619A1 (es) | Derivados halogenados de sulfonamidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |